Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 5,4x - 5,9x | 5,7x |
| Selected Fwd Revenue Multiple | 5,2x - 5,8x | 5,5x |
| Fair Value | ₩4.662 - ₩5.319 | ₩4.991 |
| Upside | 36,5% - 55,8% | 46,1% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Anygen Co., Ltd. | A196300 | KOSDAQ:A196300 |
| SCM Lifescience Co., Ltd. | A298060 | KOSDAQ:A298060 |
| GeneOne Life Science, Inc. | A011000 | KOSE:A011000 |
| Genome & Company | A314130 | KOSDAQ:A314130 |
| Cellid, Co., Ltd. | A299660 | KOSDAQ:A299660 |
| CORESTEMCHEMON Inc. | A166480 | KOSDAQ:A166480 |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| A196300 | A298060 | A011000 | A314130 | A299660 | A166480 | |||
| KOSDAQ:A196300 | KOSDAQ:A298060 | KOSE:A011000 | KOSDAQ:A314130 | KOSDAQ:A299660 | KOSDAQ:A166480 | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | -0.2% | 37.4% | -2.8% | 260.1% | NM- | 3.4% | ||
| 3Y CAGR | -15.3% | 23.4% | -2.6% | 294.7% | 66.1% | -1.7% | ||
| Latest Twelve Months | 11.0% | 18.6% | -11.2% | 94.1% | NM | -14.5% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | -51.5% | -3240.9% | -80.7% | -3537.1% | 24286174057.4% | -37.6% | ||
| Prior Fiscal Year | -119.7% | -1868.3% | -120.3% | -385.4% | NA | -58.6% | ||
| Latest Fiscal Year | -87.3% | -1371.0% | -120.5% | -87.2% | -287.6% | -76.6% | ||
| Latest Twelve Months | -87.3% | -1371.0% | -120.5% | -87.2% | -287.6% | -76.6% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 15.17x | 40.26x | 5.45x | 3.49x | 19.53x | 4.23x | ||
| EV / LTM EBIT | -17.4x | -2.9x | -4.5x | -4.0x | -6.8x | -5.5x | ||
| Price / LTM Sales | 13.93x | 32.93x | 4.74x | 3.39x | 18.54x | 2.89x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 3.49x | 15.17x | 40.26x | |||||
| Historical EV / LTM Revenue | 3.94x | 6.30x | 12.76x | |||||
| Selected EV / LTM Revenue | 5.37x | 5.66x | 5.94x | |||||
| (x) LTM Revenue | 28,762 | 28,762 | 28,762 | |||||
| (=) Implied Enterprise Value | 154,535 | 162,668 | 170,801 | |||||
| (-) Non-shareholder Claims * | (38,585) | (38,585) | (38,585) | |||||
| (=) Equity Value | 115,950 | 124,083 | 132,216 | |||||
| (/) Shares Outstanding | 24.4 | 24.4 | 24.4 | |||||
| Implied Value Range | 4,759.81 | 5,093.69 | 5,427.57 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 4,759.81 | 5,093.69 | 5,427.57 | 3,415.00 | ||||
| Upside / (Downside) | 39.4% | 49.2% | 58.9% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A196300 | A298060 | A011000 | A314130 | A299660 | A166480 | |
| Enterprise Value | 96,831 | 33,204 | 198,192 | 96,919 | 82,606 | 121,775 | |
| (+) Cash & Short Term Investments | 201 | 920 | 1,746 | 80,930 | 9,069 | 4,501 | |
| (+) Investments & Other | 1 | 0 | 18 | 0 | 0 | 3,740 | |
| (-) Debt | (7,909) | (6,966) | (27,126) | (32,024) | (13,172) | (46,826) | |
| (-) Other Liabilities | 0 | 0 | 0 | (50,753) | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | (883) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 89,124 | 27,157 | 172,831 | 94,189 | 78,503 | 83,190 | |
| (/) Shares Outstanding | 9.3 | 27.7 | 79.8 | 31.1 | 21.1 | 24.4 | |
| Implied Stock Price | 9,590.00 | 979.00 | 2,165.00 | 3,030.00 | 3,720.00 | 3,415.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 9,590.00 | 979.00 | 2,165.00 | 3,030.00 | 3,720.00 | 3,415.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |